Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Target Raised at Piper Sandler

Neurocrine Biosciences (NASDAQ:NBIX) had its target price raised by equities research analysts at Piper Sandler from $210.00 to $215.00 in a report released on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler‘s target price suggests a potential upside of 47.92% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Cantor Fitzgerald boosted their price objective on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Morgan Stanley raised their target price on shares of Neurocrine Biosciences from $182.00 to $183.00 and gave the stock an “equal weight” rating in a report on Friday, September 11th. Stifel Nicolaus lifted their price target on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wall Street Zen cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. Finally, Weiss Ratings raised Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average price target of $201.36.

Neurocrine Biosciences Trading Down 0.5%

NBIX stock opened at $145.35 on Tuesday. Neurocrine Biosciences has a 1-year low of $122.14 and a 1-year high of $186.12. The business’s 50 day simple moving average is $146.49 and its 200 day simple moving average is $147.45. The firm has a market capitalization of $14.77 billion, a PE ratio of 21.31, a PEG ratio of 0.64 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the firm posted $2.04 EPS. The company’s quarterly revenue was up 41.3% on a year-over-year basis. As a group, sell-side analysts predict that Neurocrine Biosciences will post 7.72 EPS for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 2,311 shares of Neurocrine Biosciences stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the transaction, the chief financial officer owned 42,808 shares of the company’s stock, valued at $6,729,417.60. This trade represents a 5.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David W. Boyer sold 826 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.45, for a total value of $130,053.70. Following the completion of the transaction, the insider directly owned 8,722 shares in the company, valued at approximately $1,373,278.90. This trade represents a 8.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is owned by company insiders.

Institutional Trading of Neurocrine Biosciences

Several institutional investors and hedge funds have recently modified their holdings of NBIX. Basecamp Wealth Advisors LLC grew its position in Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after purchasing an additional 204 shares in the last quarter. Raleigh Capital Management Inc. increased its stake in Neurocrine Biosciences by 561.8% in the 3rd quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock valued at $32,000 after buying an additional 191 shares during the last quarter. Cassaday & Co Wealth Management LLC bought a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $33,000. Ascentis Independent Advisors bought a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $40,000. Finally, TrinityBridge Ltd bought a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $45,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong third-quarter results: Neurocrine reported adjusted earnings of $3.29 per share, up from $2.04 a year earlier and above consensus estimates ranging from $1.91 to $2.67. Revenue increased 41.3% year over year to approximately $1.12 billion, exceeding the roughly $1.04 billion estimate. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Product sales exceeded $1 billion for the first time: Management attributed the milestone to strong demand across its portfolio of medicines, indicating continued commercial momentum and a broader revenue base. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: INGREZZA guidance raised: Neurocrine increased its 2026 net sales guidance for INGREZZA (valbenazine) to $2.9 billion-$2.925 billion. The upgraded outlook reinforces expectations for sustained demand for the company’s leading commercial product. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Neutral Sentiment: Management’s earnings-call presentations and transcripts provide additional detail on quarterly performance, product demand, and the company’s outlook. Investors will likely focus on whether the strong growth and raised guidance can continue into 2027. Neurocrine Q3 2026 Earnings Call Transcript

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.